Stephen Elledge
Founder
TScan Therapeutics
TScan Therapeutics is a clinical-stage biopharmaceutical company developing T cell therapies that harness the human immune system to target and eliminate cancer cells. Their approach addresses the limitations of traditional cancer treatments by enhancing the specificity and efficacy of immune responses against tumors.
- Biotechnology
Updated 3 days ago
Funding
Raised to date
$30MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Traditional cancer treatments often struggle to eliminate tumors completely due to a lack of specificity, leading to recurrence and off-target toxicities. Enhancing the immune system's ability to precisely target and destroy cancer cells remains a significant challenge.
Solution
TScan Therapeutics is developing T cell therapies designed to harness the human immune system's power to target and eliminate cancer cells. Their approach aims to overcome the limitations of conventional cancer treatments by improving the specificity and effectiveness of immune responses against tumors. By identifying and targeting the unique antigens present on cancer cells, TScan's therapies seek to selectively destroy tumors while minimizing damage to healthy tissues. The company is currently in clinical stages, evaluating the safety and efficacy of its T cell therapies in patients with various types of cancer.
Target Audience
The primary target audience includes patients with various types of cancer who may benefit from novel immunotherapies, as well as healthcare providers specializing in oncology.
Features
- T cell therapies designed to specifically target and eliminate cancer cells.
- Focus on enhancing the specificity and efficacy of immune responses against tumors.
- Clinical-stage development, with ongoing trials to evaluate safety and efficacy.